Last reviewed · How we verify

Universidade Federal do Ceara — Portfolio Competitive Intelligence Brief

Universidade Federal do Ceara pipeline: 1 marketed, 0 filed, 1 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 1 Phase 3 1 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
chlorhexidine digluconate chlorhexidine digluconate marketed Antimicrobial agent / Antiseptic Bacterial cell membrane and proteins Infectious Disease / Oral Care
NAC + Bromhexine (BMX) NAC + Bromhexine (BMX) phase 3 Mucolytic/secretolytic combination Respiratory/Pulmonology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. HaEmek Medical Center, Israel · 1 shared drug class
  2. Instituto de Investigacion Sanitaria La Fe · 1 shared drug class
  3. Johns Hopkins University · 1 shared drug class
  4. The Cooper Health System · 1 shared drug class
  5. Universidad de Guanajuato · 1 shared drug class
  6. University of Milan · 1 shared drug class
  7. University of Oslo · 1 shared drug class
  8. University of Pavia · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Universidade Federal do Ceara:

Cite this brief

Drug Landscape (2026). Universidade Federal do Ceara — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/universidade-federal-do-ceara. Accessed 2026-05-17.

Related